{"id":716205,"date":"2026-06-05T04:50:09","date_gmt":"2026-06-05T04:50:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/716205\/"},"modified":"2026-06-05T04:50:09","modified_gmt":"2026-06-05T04:50:09","slug":"building-a-stronger-first-line-of-defence-against-respiratory-viruses","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/716205\/","title":{"rendered":"Building a stronger first line of defence against respiratory viruses"},"content":{"rendered":"<p>Respiratory viruses continue to place significant pressure on communities and healthcare services each winter. During the peak of the 2025 flu season, <a href=\"https:\/\/www.health.nsw.gov.au\/Infectious\/covid-19\/Pages\/weekly-reports-archive.aspx#2025\" target=\"_blank\" rel=\"noopener nofollow\">more than 1,000 people were presenting to NSW emergency departments each week with influenza-like illness<\/a>.<\/p>\n<p>For Professor Nathan Bartlett, a virologist at the University of Newcastle and leader of HMRI\u2019s Infection Research Program, those numbers highlight the need for better ways to stop infections before they take hold.<\/p>\n<p>Respiratory viruses such as influenza, RSV and COVID-19 can have serious consequences for older adults, young children and people living with chronic health conditions. Finding new ways to prevent these infections before they cause harm has been a major focus of Professor Bartlett\u2019s research career.<\/p>\n<p>Now a promising nasal spray he helped develop is advancing through clinical trials in the United States, bringing that goal one step closer to reality.<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"473\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/06\/Nasal-Spray-2-1024x473.jpg\" alt=\"Nasal Spray 2\"  \/><\/p>\n<p>A new way to fight respiratory viruses<\/p>\n<p>Professor Bartlett spent five years leading preclinical research on INNA-051, an investigational nasal spray designed to boost the body\u2019s natural immune defences against respiratory viruses.<\/p>\n<p>Rather than targeting a single virus, INNA-051 works by activating the innate immune system, the body\u2019s first line of defence against infection.<\/p>\n<p>\u201cThe idea is to boost the body\u2019s natural ability to protect itself from respiratory viruses,\u201d Professor Bartlett said.<\/p>\n<p>\u201cMost viruses, including influenza, RSV and COVID-19, enter through the nose. If we can activate the immune system at that point of entry, we can help stop the virus before it establishes an infection.<\/p>\n<p>\u201cInstead of targeting one specific virus, we\u2019re enhancing the body\u2019s broader antiviral response, which means it has the potential to protect against a range of respiratory infections.\u201d<\/p>\n<p>From an unexpected discovery to a global research program<\/p>\n<p>Professor Bartlett\u2019s involvement began after researchers at Melbourne\u2019s Doherty Institute made an intriguing observation.<\/p>\n<p>The compound behind INNA-051 had originally been developed to improve vaccine effectiveness, but researchers noticed it appeared to provide protection against influenza even without a vaccine.<\/p>\n<p>\u201cThey asked me to design a program to prove it works, or doesn\u2019t work,\u201d Professor Bartlett said. \u201cThat\u2019s how my involvement started.\u201d<\/p>\n<p>Over the following five years, University of Newcastle and HMRI researchers worked alongside collaborators in Australia and the United Kingdom to test the compound against a range of respiratory viruses, including rhinoviruses, coronaviruses, influenza and SARS-CoV-2.<\/p>\n<p>\u201cMy role in Newcastle was one of the preclinical leads working on initial validation of the drug and its effect on viruses,\u201d Professor Bartlett said.<\/p>\n<p>\u201cWe were there at the start, getting the evidence needed to raise the money so they could go with a big clinical trial.\u201d<\/p>\n<p>Moving closer to patients<\/p>\n<p>The early research helped pave the way for clinical development.<\/p>\n<p>Melbourne-based biotechnology company ENA Respiratory has since secured more than $46 million in funding from organisations including the Gates Foundation and Minderoo Foundation, as well as an $18 million contract with the United States Department of Defence.<\/p>\n<p>A Phase 2 clinical trial is now underway in the United States. Following a successful safety study involving 200 participants, a larger trial involving 900 people is planned later this year.<\/p>\n<p>The study will focus on people at increased risk of exposure to respiratory viruses, including those living in university accommodation, households with young children and childcare settings.<\/p>\n<p>For Professor Bartlett, the progress represents much more than a scientific milestone.<\/p>\n<p>\u201cYou hope all that work you did makes it through clinical development and eventually ends up in doctors\u2019 hands treating patients,\u201d he said.<\/p>\n<p>\u201cIt would protect those at high risk of nasty outcomes.\u201d<\/p>\n<p>A timely reminder as winter approaches<\/p>\n<p>Recent <a href=\"https:\/\/info.flutracking.net\/reports\/australia-reports\/\" target=\"_blank\" rel=\"noopener nofollow\">FluTracking data<\/a> showed respiratory illness activity rising as winter approached, highlighting the continued impact respiratory viruses have on communities across Australia.<\/p>\n<p>The rise serves as a timely reminder that communities can\u2019t afford to be complacent when it comes to respiratory illness and should take steps to reduce their risk of infection this winter.<\/p>\n<p>For Professor Bartlett, while new treatments and preventions are important, simple public health measures remain one of the most effective ways to protect yourself and others.<\/p>\n<p>\u201cVaccination remains one of the most effective ways to protect yourself and those around you from serious illness,\u201d Professor Bartlett said.<\/p>\n<p>\u201cIf you\u2019re unwell, stay home where possible, practise good hand hygiene and try to avoid close contact with people who may be vulnerable.<\/p>\n<p>\u201cRespiratory viruses spread very easily, but small actions can make a big difference in protecting our families, workplaces and communities.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Respiratory viruses continue to place significant pressure on communities and healthcare services each winter. During the peak of&hellip;\n","protected":false},"author":2,"featured_media":716206,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[64,63,128],"class_list":["post-716205","post","type-post","status-publish","format-standard","has-post-thumbnail","category-science","tag-au","tag-australia","tag-science"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/716205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=716205"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/716205\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/716206"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=716205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=716205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=716205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}